Sandoz

Sandoz Anticipates Continued Sales Growth Driven by New Biosimilars

29 days ago

In a significant move poised to bolster its market position, Sandoz, a leading global supplier of generic pharmaceuticals and biosimilars, has announced its optimistic outlook for sales driven by the introduction of new biosimilar products. The company forecasts steady growth as it expands its portfolio in this fast-evolving segment of the pharmaceutical industry.

Insights from Sandoz CEO Richard Saynor on Ozempic, Big Pharma Struggles, and Political Influences

3 months ago

In a candid conversation, Richard Saynor, CEO of Sandoz, provided a deep dive into the complexities surrounding the pharmaceutical landscape, including the rising prominence of Ozempic, challenges facing the industry, and the influence of political figures such as Donald Trump. Saynor’s insights shed light on the evolving narratives within Big Pharma and the implications for patients, healthcare, and future drug development.

Sandoz Strategizes Quick Launch of Generic Ozempic in Canada

4 months ago

Sandoz, a subsidiary of Novartis, has unveiled its plans to swiftly introduce a generic version of the diabetes medication Ozempic in Canada. This move comes amid rising demand for affordable diabetes treatment options in the country, where the cost of medications has been a significant concern for many patients and healthcare providers alike.